HN30.F Restart Life Sciences Corp.

Healthcare Biotechnology Frankfurt Exchange
0.0430 EUR
Close of Nov 12, 2026
0.0365 0.0785
Market cap
EUR 2.69M
P/E
-
P/B
2.73x
ROE
-202.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HN30.F undervalued?

Graham number

The Graham number of Restart Life Sciences Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Restart Life Sciences Corp. fundamental analysis

No fundamental analysis for Restart Life Sciences Corp. yet.

Restart Life Sciences Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Restart Life Sciences Corp.

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the developm…

Full company profile